• AXT, Inc. recently updated its fourth-quarter 2025 revenue expectations and, at the 28th Annual Needham Growth Conference in New York, discussed how Chinese export permit constraints for indium phosphide limited shipments despite firm demand.
• The company also highlighted plans to more than double its indium phosphide capacity in the second half of 2026, funded in part by a December capital raise aimed at supporting AI-related data center infrastructure and high-speed optical connectivity.
• Next, we’ll examine how constrained Chinese export permits and AXT’s capacity expansion plans may reshape its existing investment narrative.

Rare earth metals are the new gold rush. Find out which 38 stocks are leading the charge.

AXT Investment Narrative Recap

To own AXT, you need to believe its compound semiconductor substrates will convert AI and high-speed optical demand into sustainable, profitable growth despite current losses and volatility. The latest export permit shortfall directly affects the key near term catalyst of converting strong indium phosphide demand into revenue, while reinforcing that the biggest risk remains ongoing Chinese permit uncertainty that can disrupt shipments and cash flow.

The December follow on equity raise of about US$87,000,000 ties directly to this update, because it funds AXT’s plan to more than double indium phosphide capacity in the second half of 2026. For investors focused on catalysts, this combination of added capital and targeted expansion sets up a clear test of whether regulatory bottlenecks ease in time for AXT to benefit from AI data center and high speed connectivity demand.

Yet behind the growth story, investors should be aware of how prolonged export permit constraints could...

AXT's narrative projects $117.8 million revenue and $16.6 million earnings by 2028.

Uncover how AXT's forecasts yield a $9.50 fair value, a 57% downside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently place AXT’s fair value between US$5.70 and US$9.50, highlighting a wide spread of opinion. You should weigh these differing views against the risk that Chinese export permit constraints for key substrates could continue to create revenue volatility and pressure on margins, with clear implications for how the business performs over time.

Explore 3 other fair value estimates on AXT - why the stock might be worth as much as $9.50!

Build Your Own AXT Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your AXT research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free AXT research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AXT's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.